Minneapolis just landed in the middle of one of this year’s biggest life-science shakeups. Bio‑Techne, the Minneapolis-based maker of research reagents and instruments, agreed Thursday to be acquired by Germany’s Merck in an all-cash deal that values the company at roughly $11.3 billion, or $73 a share. The transaction would fold Bio‑Techne’s multi-omics, spatial-biology and analytical platforms into Merck’s Life Science business, instantly placing the deal among the sector’s largest this year.
In a joint announcement, Merck and Bio‑Techne said the $73-per-share offer, an enterprise value of about US$11.3 billion, represents a roughly 36% premium to Bio‑Techne’s recent trading and will be funded through a combination of existing cash and new debt. Merck is forecasting about €140 million in cost synergies and expects the merger to be accretive to earnings by year three. The deal is subject to customary closing conditions, including required regulatory approvals and a vote by Bio‑Techne shareholders, with an anticipated close in late 2026 or early 2027, according to PR Newswire.
What Merck Bought
Bio‑Techne supplies proteins, antibodies, analytical instruments and diagnostics used across academic and commercial research. The portfolio includes the RNAscope in-situ hybridization platform and ProteinSimple automated analyzers that Merck highlighted as complementary to its existing process and analytical offerings. “This transaction is a testament to the remarkable company our team has built,” Bio‑Techne CEO Kim Kelderman said in the announcement, as reported by PR Newswire.
Market Reaction And The Bigger Picture
Investors did not wait around. Bio‑Techne shares jumped more than 20% in early trading after the news, according to market reports. Reuters covered the market move, while industry reporting at Bloomberg Law noted that the acquisition is Merck’s largest in more than a decade, a clear signal that the company is doubling down on life-science tools and analytics as a strategic growth area.
What This Means For Minneapolis
Bio‑Techne is headquartered in Minneapolis at 614 McKinley Place NE and reported roughly $1.22 billion in net sales for fiscal 2025, making it one of the region’s larger life-science employers and a key supplier to academic and commercial labs. Those details appear in the company’s recent SEC filings and investor materials, which local stakeholders will be watching closely as Merck rolls out its integration plans (Bio-Techne).
For customers and regional partners, the immediate questions revolve around continuity of supply, product road maps and whether Merck invests further in local research or consolidates operations elsewhere. For investors, attention now turns to the proxy timeline, any regulatory feedback and the fine print of the integration plan that Merck and Bio‑Techne say they will spell out in upcoming filings and briefings.
